Heron Therapeutics Inc vs Logitech International SA — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Logitech International SA trades at $103.79 (market cap $15.18B). The key difference: Logitech International SA is far larger — about 239.4× Heron Therapeutics Inc's market cap, and Logitech International SA pays a 1.62% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | LOGI | |
|---|---|---|
Market Cap | $63.41M | $15.18B |
Sector | Health | Technology |
52-Week High | $1.49 | $126.69 |
52-Week Low | $0.32 | $85.84 |
Enterprise Value | $161.31M | $13.52B |
Dividend Yield | — | 1.62% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Logitech (LOGI) trades at $106.33, up 3.26% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue is projected to grow to $4.9B in 2026, with net income margin improving to 16.27%. The company faces near-term supply chain risks from a key semiconductor supplier shutdown, but strong demand in gaming and premium devices supports growth.
The outlook is mixed: solid fundamentals and analyst consensus target of $109.75 suggest upside, but supply constraints and mixed analyst ratings (26% Buy, 47% Hold, 26% Sell) indicate caution. Investors should weigh robust profitability against operational risks in the coming quarters.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →